<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181310</url>
  </required_header>
  <id_info>
    <org_study_id>3134-005</org_study_id>
    <secondary_id>2007-001894-27</secondary_id>
    <nct_id>NCT01181310</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)</brief_title>
  <official_title>A Five-Period, Placebo-Controlled, Crossover Study to Evaluate the Effect of Donepezil and MK-3134 on Reversal of Cognitive Impairment Associated With a Single-Dose of Scopolamine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drug, scopolamine, can result in short-term impairments of cognitive function, attention,
      and memory that resemble those seen in aging and Alzheimer's disease. This study tested the
      capability of both individual and combined doses of MK-3134 and the current standard
      treatment: donepezil (Aricept), to reverse such impairments, following a single dose of
      scopolamine. Participants were evaluated after each of 5 different treatment periods (in a
      cross-over, double-dummy design): A: placebo to match both donepezil (oral [PO]) and MK-3134
      (PO) followed by placebo scopolamine (subcutaneous [SQ]); B: placebo to match both donepezil
      (PO) and MK-3134 (PO), followed by scopolamine SQ; C: MK-3134 (PO) followed by scopolamine
      SQ; D: donepezil (PO) followed by scopolamine SQ; E: MK-3134 (PO) and donepezil (PO) followed
      by scopolamine SQ. The doses of MK3134, donepezil, and scopolamine were the same over all
      treatment arms in which the specified drug was administered. There were 8 total visits for
      each treatment period, including 5 Treatment Visits requiring 14-day intervals between visits
      for study-drug washout. Participants were assessed for cognitive function before and after
      each treatment period during the Treatment Visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CogState Early Phase Battery, Groton Maze Learning Test (GMLT) as measured by the number of errors on the GMLT over time (area under the GMLT-time curve) over hours 1-12.</measure>
    <time_frame>1, 2, 3, 4, 6, 8, and 12 hours relative to administration of SQ scopolamine or SQ placebo</time_frame>
    <description>Participants learned a hidden pathway through a maze (10 x 10 grid of tiles on a computer touch screen) using step-by-step guess, with trial and error feedback after each step. Once the pathway was learned, participants repeated the same pathway four more times. The number of pathway errors was used to indicate the level of cognitive function.</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>A, B, D, E, C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, C, E, A, D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C, D, A, B, E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D, E, B, C, A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E, A, C, D, B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A, C, B, E, D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, D, C, A, E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C, E, D, B, A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D, A, E, C, B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E, B, A, D, C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine</intervention_name>
    <description>Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.</description>
    <arm_group_label>A, B, D, E, C</arm_group_label>
    <arm_group_label>B, C, E, A, D</arm_group_label>
    <arm_group_label>C, D, A, B, E</arm_group_label>
    <arm_group_label>D, E, B, C, A</arm_group_label>
    <arm_group_label>E, A, C, D, B</arm_group_label>
    <arm_group_label>A, C, B, E, D</arm_group_label>
    <arm_group_label>B, D, C, A, E</arm_group_label>
    <arm_group_label>C, E, D, B, A</arm_group_label>
    <arm_group_label>D, A, E, C, B</arm_group_label>
    <arm_group_label>E, B, A, D, C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg</intervention_name>
    <description>Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.</description>
    <arm_group_label>A, B, D, E, C</arm_group_label>
    <arm_group_label>B, C, E, A, D</arm_group_label>
    <arm_group_label>C, D, A, B, E</arm_group_label>
    <arm_group_label>D, E, B, C, A</arm_group_label>
    <arm_group_label>E, A, C, D, B</arm_group_label>
    <arm_group_label>A, C, B, E, D</arm_group_label>
    <arm_group_label>B, D, C, A, E</arm_group_label>
    <arm_group_label>C, E, D, B, A</arm_group_label>
    <arm_group_label>D, A, E, C, B</arm_group_label>
    <arm_group_label>E, B, A, D, C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C: MK-3134 25 mg + Scopolamine 0.5 mg</intervention_name>
    <description>A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.</description>
    <arm_group_label>A, B, D, E, C</arm_group_label>
    <arm_group_label>B, C, E, A, D</arm_group_label>
    <arm_group_label>C, D, A, B, E</arm_group_label>
    <arm_group_label>D, E, B, C, A</arm_group_label>
    <arm_group_label>E, A, C, D, B</arm_group_label>
    <arm_group_label>A, C, B, E, D</arm_group_label>
    <arm_group_label>B, D, C, A, E</arm_group_label>
    <arm_group_label>C, E, D, B, A</arm_group_label>
    <arm_group_label>D, A, E, C, B</arm_group_label>
    <arm_group_label>E, B, A, D, C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D: Donepezil 10 mg + Scopolamine 0.5 mg</intervention_name>
    <description>A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.</description>
    <arm_group_label>A, B, D, E, C</arm_group_label>
    <arm_group_label>B, C, E, A, D</arm_group_label>
    <arm_group_label>C, D, A, B, E</arm_group_label>
    <arm_group_label>D, E, B, C, A</arm_group_label>
    <arm_group_label>E, A, C, D, B</arm_group_label>
    <arm_group_label>A, C, B, E, D</arm_group_label>
    <arm_group_label>B, D, C, A, E</arm_group_label>
    <arm_group_label>C, E, D, B, A</arm_group_label>
    <arm_group_label>D, A, E, C, B</arm_group_label>
    <arm_group_label>E, B, A, D, C</arm_group_label>
    <other_name>Aricept (donepezil)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg</intervention_name>
    <description>A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.</description>
    <arm_group_label>A, B, D, E, C</arm_group_label>
    <arm_group_label>B, C, E, A, D</arm_group_label>
    <arm_group_label>C, D, A, B, E</arm_group_label>
    <arm_group_label>D, E, B, C, A</arm_group_label>
    <arm_group_label>E, A, C, D, B</arm_group_label>
    <arm_group_label>A, C, B, E, D</arm_group_label>
    <arm_group_label>B, D, C, A, E</arm_group_label>
    <arm_group_label>C, E, D, B, A</arm_group_label>
    <arm_group_label>D, A, E, C, B</arm_group_label>
    <arm_group_label>E, B, A, D, C</arm_group_label>
    <other_name>Aricept (donepezil)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants were eligible for inclusion in the study who were:

          -  Male between 18 and 40 years of age.

          -  Non-smokers, in good health (as defined in protocol), and were willing to follow
             study-related procedures.

        Participants were not eligible for inclusion in the study if they:

          -  Had a history of illness that, in the opinion of the study investigator or as
             specified in protocol, might confound the results of the study or posed an potential,
             additional risk to the participant if they were to participate in the study.

          -  Were taking any medication (prescription, nonprescription, vitamin supplements or
             herbal, illicit or legitimate) except for acetaminophen.

          -  Had a history of any significant head injury/trauma.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>November 5, 2015</last_update_submitted>
  <last_update_submitted_qc>November 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dementia, cognitive impairment, neurodegeneration, Alzheimer's, acetylcholine, AchE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

